CPT code 81210 – BRAF gene variant analysis

Key takeaways

CPT code 81210 covers somatic BRAF V600 variant analysis (V600E, V600K, V600D, V600R), not germline hereditary cancer testing.

It is a Tier 1 molecular pathology code that Medicare pays on the Clinical Laboratory Fee Schedule.

Medical necessity rests on a treating physician order naming the gene, a pathology report confirming tumor tissue, and a note linking the result to treatment.

In MolDX jurisdictions (Palmetto GBA, Noridian, CGS and WPS), labs complete a technical assessment and use a DEX Z-code where the policy requires one.

Pabau, our practice management platform, keeps the order and rationale note on the encounter record and submits and tracks each 81210 claim electronically.

CPT code 81210: Official descriptor and quick reference

CPT code 81210 describes BRAF (B-Raf proto-oncogene, serine/threonine kinase) gene analysis for V600 variant(s). Labs bill it for somatic tumor testing in cancers such as colon cancer and melanoma. The American Medical Association’s CPT code set places 81210 in the molecular pathology range as a Tier 1 code. Tier 1 codes (81200-81383) each name one specific gene, while Tier 2 codes (81400-81408) group less common tests by resource level.

Medicare pays 81210 on the Clinical Laboratory Fee Schedule (CLFS). The code covers the whole analytic service for the BRAF V600 analysis. Billing separate codes for PCR runs or sequencing steps on the same gene is unbundling.

What does CPT 81210 cover? Procedure scope and gene variants

CPT 81210 covers single-gene analysis of BRAF for variants at the V600 codon. V600E (Val600Glu) is the most frequently tested variant and accounts for most BRAF mutations across tumor types. The code also covers V600K, V600R and V600D when the method detects them in the same analytic run.

Allele-specific PCR, Sanger sequencing, pyrosequencing and real-time PCR assays designed for the V600 hotspot all fall under the code. Accepted specimens include formalin-fixed paraffin-embedded (FFPE) tissue from resection or biopsy, and fresh or frozen tumor tissue. Cell-free DNA from a liquid biopsy also qualifies when the assay is validated for that matrix.

• Included: V600E, V600K, V600R and V600D variant analysis by any method targeting the V600 codon region
• Included: Tissue biopsy specimens and validated liquid biopsy specimens
• Excluded: BRAF variants outside the V600 segment (use 81479 for unlisted molecular pathology)
• Excluded: Multi-gene panels that include BRAF alongside other genes (use 81445 or 81455 depending on gene count)
• Excluded: Germline BRAF testing for hereditary cancer syndrome evaluation, which falls under a different coverage policy

Clinical indications: When is CPT 81210 medically necessary?

CPT 81210 is medically necessary when BRAF V600 status directly informs a therapeutic decision, either selecting a targeted agent or ruling one out. NCCN Clinical Practice Guidelines in Oncology recognize four primary tumor types where this applies.

The clinical record must document the tumor stage or extent of disease and the treating physician’s reason for ordering the test. It should also state that the result will shape the treatment plan. The MolDX Molecular Diagnostic Tests LCDs (L36256 and L35160) and the MolDX billing article for FDA-approved BRAF tests (A54418) require that link. A diagnosis without the therapeutic rationale does not meet Medicare coverage.

Accepted ICD-10-CM codes to pair with CPT 81210

Payers validate 81210 claims by checking the submitted diagnosis code against their coverage criteria. An unspecified code, or an encounter code without a confirmed malignancy code, is a common cause of automatic denial. Pair 81210 with the primary malignancy code, such as C20 for a rectal tumor, not a screening or family history code.

Z-codes such as Z15.09 (genetic susceptibility to other malignant neoplasm) and encounter-only codes should not be the primary diagnosis on a CPT 81210 claim. Some payers also reject an “unspecified” code when the medical record supports a more specific one.

Medicare and payer coverage for CPT 81210

Medicare covers CPT 81210 under the Clinical Laboratory Fee Schedule (CLFS), and CMS updates the rate each January. Check the current figure in the CMS CLFS file rather than relying on a number in a billing guide. Confirm it there before you load a dollar amount into an internal fee schedule.

Medicare molecular testing falls under the MolDX program in the Palmetto GBA, Noridian, CGS and WPS jurisdictions. A lab billing 81210 there completes a MolDX technical assessment and registers the test through DEX, the MolDX Diagnostics Exchange. DEX issues the Z-Code Identifier that goes on the claim where the MolDX policy requires one.

When the technical assessment is missing, claims can deny in bulk. Registering the test clears them faster than appealing claim by claim.

• Palmetto GBA / Noridian / CGS / WPS (MolDX): MolDX technical assessment, plus a DEX Z-code where the MolDX policy requires one
• Other MACs (Novitas, NGS): Coverage articles may differ, so check the LCD for the jurisdiction where the lab is enrolled
• Commercial payers (UnitedHealthcare, Aetna, BCBS, Cigna, Humana): Policies vary by plan. Check each payer’s current molecular testing policy for prior-auth rules

Prior authorization requirements for CPT 81210

Prior authorization for CPT 81210 is not universal, but many commercial payers require it for outpatient oncology testing. It depends on the payer, the plan type and whether the order comes from an inpatient or outpatient setting. Run insurance eligibility verification and confirm benefits before the lab processes the specimen.

When prior auth is required, the submission package typically needs four items.

• The treating physician’s order specifying BRAF V600 variant analysis
• The pathology report or biopsy confirmation showing a tumor specimen
• Clinical notes documenting the disease stage and the therapeutic rationale
• A citation to the NCCN guideline that supports the testing indication

For urgent oncology cases, many payers offer an expedited review, often with a 24-to-72-hour turnaround.

CPT 81210 vs. related codes: Avoiding unbundling and upcoding

Most coding confusion around 81210 involves a handful of adjacent codes. Billing the wrong one, or several codes for one service, creates unbundling exposure and audit risk.

The order settles most of these choices before anyone opens a code book, as the chart below shows. A BRAF assay aimed at variants outside V600 goes to 81479, the unlisted molecular pathology code.

NCCI edits between 81210 and the panel codes, 81445 or 81455 depending on gene count, are updated quarterly. A lab running a solid-organ NGS panel and a standalone BRAF test on the same specimen date must check the current edit table first. The edit may allow both codes with a modifier, or it may allow only the panel code.

Check the AAPC Codify CPT lookup and the CMS NCCI edit files for the current quarter before billing both.

Documentation requirements for successful CPT 81210 claims

Documentation for 81210 has to line up in two places: the ordering provider’s clinical record and the laboratory’s internal file. A claim backed by one but not the other will fail a medical necessity review. Good medical billing compliance practice is to audit both before submission.

• Treating physician order: Names BRAF as the gene, specifies V600 variant analysis, and states the clinical indication. An example is “metastatic colorectal cancer, BRAF status to determine anti-EGFR therapy eligibility.”
• Pathology report: Confirms the specimen is tumor-derived and records tissue type, collection date and tumor percentage
• Clinical notes: Document disease stage, prior treatments, and an explicit statement that the result will inform the next therapeutic decision
• Somatic vs. germline attestation: The record shows the test is somatic (an acquired tumor mutation), not a germline hereditary screen. A missing attestation is a common cause of denial.
• Date of service: Normally the date the specimen was collected. CMS date-of-service exceptions, such as the 14-day rule for stored hospital specimens, can set it to the date the test is performed.

Common denial reasons for CPT 81210 and how to appeal

Denials on CPT code 81210 tend to follow five patterns. Read the claim adjustment reason code (CARC) and remark code (RARC) on the remittance before you draft an appeal. The root cause decides the fix.

An NCCI edit conflict usually comes back as CO-97 or CO-236 rather than CO-4. Appeal timeframes typically run 60 to 180 days from the remittance date, depending on the payer. For Medicare, the first-level redetermination request must be filed within 120 days of the initial determination.

Structured denial management workflows track each denial code, its root cause and the appeal due date, so claims do not age past the filing limit. Our guide to denial reason codes maps each CARC code to an appeal strategy.

How Pabau keeps CPT 81210 claims documented

A BRAF order passes through three handoffs: the ordering visit, specimen receipt at the lab, and the claims queue. A missing somatic-versus-germline note, NCCN citation or prior authorization at any of them can surface as a denial weeks later.

Pabau keeps the treating physician order, the pathology report reference and the therapeutic rationale note on the encounter record. Its claims management software submits and tracks claims electronically, so your team can see where each 81210 claim stands.

When a medical necessity appeal arrives, the supporting documents are already on file. For practices handling revenue cycle management across several oncology providers, that keeps denial deadlines in view.

Keep CPT 81210 claims documented from order to payment

Pabau keeps the BRAF order, pathology reference and rationale note on the encounter record. It submits and tracks each 81210 claim electronically, so an appeal starts from documents already on file.

Book a demo

Conclusion

Bill 81210 only when the order, the pathology report and the clinical note all point to somatic BRAF V600 testing for a treatment decision. If one of the three is missing, fix the record before the claim goes out.

Settle two payer questions before the specimen runs: MolDX registration in MolDX states, and the prior-auth rule in the commercial plan. Both cost less to answer at the order than in an appeal.

Book a demo to see how Pabau keeps BRAF orders, pathology references and claim status together on one encounter record.

Continue your research

Need a clearinghouse for molecular pathology claims? Pabau’s Claim.MD clearinghouse integration explains how claims reach US payers electronically and how their status comes back.

Want to understand what a clean claim looks like before submission? What makes a clean claim walks through the data elements payers validate on every submission.

Looking for the broader context of medical billing for labs? Medical billing fundamentals covers the revenue cycle from order to payment posting.

Frequently asked questions